New Weight-Loss drug ZT002 enters early human testing
NCT ID NCT06371326
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested the safety and tolerability of ZT002, an injectable drug for weight loss, in 28 adults with overweight or obesity. Participants received multiple doses of ZT002 or a placebo to see how the body processes the drug and if any side effects occur. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZT002 injection
What this could lead to
If safe and effective, ZT002 could become a new treatment option for weight management in people with overweight or obesity.
What could go wrong
This is a very early Phase 1 trial with only 28 participants, so it's too soon to know if ZT002 works or is safe long-term. Side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Bengbu Medical College
Bengbu, China